Equity Overview
Price & Market Data
Price: $1.00
Daily Change: $0.00 / 0.00%
Daily Range: $0.939 - $1.12
Market Cap: $3,804,360
Daily Volume: 167,221
Performance Metrics
1 Week: -33.34%
1 Month: -49.50%
3 Months: -45.06%
6 Months: -59.19%
1 Year: -89.32%
YTD: -45.06%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.